Department of Haemato-Oncology, University Hospital in Pilsen, Pilsen, Czech Republic.
Med Sci Monit. 2011 Oct;17(10):CR572-6. doi: 10.12659/msm.881983.
Gelclair is an oral lubricating gel used in the management of oral mucositis (OM). We evaluated its efficacy, tolerance and impact on oral cavity microbial colonization in patients with OM after allogeneic hematopoietic stem cells transplantation.
MATERIAL/METHOD: Gelclair was administered in a group of 22 patients with active OM. A control group of 15 patients used other rinsing solutions (chlorhexidine, benzydamine, salvia). Tests with oral cavity swabs for microbiology analysis were performed once a week.
The characteristics of OM in both groups were comparable, and rinsing solutions had satisfactory tolerability. There was no difference in the median improvement of oral intake and OM-related pain relief, which was assessed mostly as "slight effect". In the Gelclair group, the effect duration was longer (median 3 [0-5] vs. 1 [0-3] hours, p = 0.001). There was significant increase of Enterococcus faecalis and Candida sp. colonization of the oral cavity over the course of the hospitalization and significantly reduced incidence of such colonization in patients with OM in the Gelclair group: 1/22 (5%) vs. 6/15 (40%), p = 0.01. In vitro tests showed inhibited growth of Enterococcus faecalis and Candida sp. colonies within the area of the Gelclair application.
Gelclair may be individually helpful in the management of OM and pain in patients after allogeneic stem cells transplantation. Its use did not lead to worsened oral bacterial and yeast colonization and probably even helped to protect mucosa from Enterococcus and Candida sp. Further studies based on larger cohorts are needed.
Gelclair 是一种口腔润滑凝胶,用于治疗口腔黏膜炎(OM)。我们评估了其在异基因造血干细胞移植后 OM 患者中的疗效、耐受性和对口腔微生物定植的影响。
材料/方法:Gelclair 组 22 例患者使用 Gelclair 治疗活动期 OM,对照组 15 例患者使用其他漱口液(洗必泰、苯扎氯铵、丹参)。每周进行一次口腔拭子微生物学检测。
两组 OM 的特征相似,漱口液具有良好的耐受性。口腔摄入和 OM 相关疼痛缓解的中位数改善无差异,主要评估为“轻微效果”。Gelclair 组的作用持续时间更长(中位数 3 [0-5] vs. 1 [0-3] 小时,p = 0.001)。住院期间口腔内粪肠球菌和念珠菌定植明显增加,Gelclair 组 OM 患者的定植发生率明显降低:1/22(5%)vs. 6/15(40%),p = 0.01。体外试验表明,Gelclair 可抑制应用区域内粪肠球菌和念珠菌菌落的生长。
Gelclair 可能有助于异基因干细胞移植后 OM 和疼痛患者的个体化治疗。其使用不会导致口腔细菌和酵母定植恶化,甚至可能有助于保护黏膜免受肠球菌和念珠菌的侵袭。需要进一步基于更大队列的研究。